Segment Information

3 Months Ended

Mar. 31, 2013

Segment Information [Abstract]

Segment Information

Note 9. Segment Information

Effective October 1, 2012, we commenced reporting the results of our operations in two segments; Pharmaceutical Products and Health Sciences Products. We established these two segments following our acquisition of To Go Brands, which presented us with a turn-key opportunity to acquire a limited but established portfolio of nutritional supplement or “neutraceutical” products. We manage these two segments separately due to inherent differences in the nature of pharmaceutical and nutraceutical products. Pharmaceutical products are subject to significantly more stringent regulatory approval standards than nutraceutical products; there are material differences in the cost, time and effort we must expend to develop and test pharmaceutical products, each of these product categories have distinctly different marketing channels and the initial sales ramp is much slower for our products in the Pharmaceutical segment.

The Nutraceutical segment of our business includes the purchasing, packaging, selling and distribution of the To Go Brands portfolio of products that we acquired on September 28, 2012. The Pharmaceutical segment of our business, which is our core and planned principal operation, includes the development, testing and clinical trials of Generx and Excellagen products. We do not have an internal sales force for our pharmaceutical products and will rely on strategic partnerships and distribution agreements in the U.S. and internationally. We have distributed samples and made initial sales of Excellagen and have entered into distribution agreements for future sales growth.

The following is a summary of certain financial data for each of our business segments:

	Three Months Ended March 31, 2013		Three Months Ended March 31, 2012
Net Sales
Pharmaceutical	$	47,400	$	0
Nutraceutical		551,805		20,478
Total		599,205		20,478

	Three Months Ended March 31, 2013		Three Months Ended March 31, 2012
Operating Loss
Pharmaceutical		1,975,253		2,519,871
Nutraceutical		286,409		139,466
Total		2,261,662		2,659,337
	March  31, 2013		December 31, 2012
Identifiable Assets
Pharmaceutical		4,643,316		7,167,478
Nutraceutical		818,330		641,400
Total	$	5,461,646	$	7,808,878